FIELD: medicine.
SUBSTANCE: suggested is the use of N,N'-bis[2-(1H-imidazol-4-yl)ethyl]isophthalamide or its pharmaceutically acceptable salt, hydrate or solvate for the treatment of a disorder, Crohn's disease, ulcerative colitis, peritonitis, nephropathy, or kidney disease, which is a side effect of the use of drugs. Also provided is a process for treating the disease, including administration of the said compound in a therapeutically effective amount.
EFFECT: technical result is the use of a compound that is effective in modulating glutaminyl cyclase in the treatment of diseases associated with aberrant activity of immune system cells.
4 cl, 6 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW INHIBITOR OF GLUTAMINYL CYCLASE AND ITS USE | 2017 |
|
RU2665633C1 |
| NEW INHIBITOR OF GLUTAMINYL CYCLASE AND ITS USE FOR TREATMENT OF LUNG AND RESPIRATORY DISEASES | 2017 |
|
RU2662559C1 |
| NEW ZINC COMPLEX, ITS PREPARATION AND APPLICATION FOR THERAPY OF HUMAN AND ANIMAL DISEASES | 2018 |
|
RU2697580C1 |
| COMPOSITION FOR THE TREATMENT OF FELINE INFECTIOUS PERITONITIS | 2021 |
|
RU2780097C1 |
| MEDICAL APPLICATION OF ARTEMISININ DERIVATIVES FOR TREATMENT OF INFLAMMATORY INTESTINAL DISEASE | 2018 |
|
RU2746707C1 |
| COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES | 2010 |
|
RU2569109C2 |
| METHOD OF IMMUNOCORRESPONDENCE IN CASE OF PURULENT PERITONITIS | 1992 |
|
RU2026678C1 |
| CHEMICAL COMPOUNDS I | 2005 |
|
RU2381216C2 |
| TREATMENT OF INFLAMMATION, AUTOIMMUNE, AND NEURODEGENERATIVE DISORDERS WITH IMMUNOSUPPRESSIVE TAT DERIVATIVE POLYPEPTIDES | 2013 |
|
RU2653754C2 |
| NEW EP4 AGONIST | 2011 |
|
RU2564414C2 |
